LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Inicio・Lista de Acciones・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Cerrado

SectorSanidad

21.45 -0.23

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

21.45

Máximo

21.45

Métricas clave
By Trading Economics
Ingresos	-1.6M -21M
Ventas	14M 54M
Margen de beneficios	-39.611
Empleados	178
EBITDA	-3.8M -23M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	-3.62% downside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	1B 2.2B
Apertura anterior	21.68
Cierre anterior	21.45

Noticias sobre sentimiento de mercado

By Acuity

50%

171 / 346 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

6.26 / 7.47 Soporte y Resistencia

Day One Biopharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 may 2026, 22:44 UTC

Adquisiciones, fusiones, absorciones

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 may 2026, 22:27 UTC

Adquisiciones, fusiones, absorciones

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 may 2026, 22:12 UTC

Ganancias

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 may 2026, 21:52 UTC

Adquisiciones, fusiones, absorciones

LVMH to Sell Marc Jacobs

15 may 2026, 00:00 UTC

Ganancias

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 may 2026, 23:57 UTC

Adquisiciones, fusiones, absorciones

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 may 2026, 23:56 UTC

Adquisiciones, fusiones, absorciones

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 may 2026, 23:56 UTC

Adquisiciones, fusiones, absorciones

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 may 2026, 23:56 UTC

Charlas de Mercado

Gold Prices Rise on Strong Demand -- Market Talk

14 may 2026, 23:56 UTC

Adquisiciones, fusiones, absorciones

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 may 2026, 23:50 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 may 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 may 2026, 23:47 UTC

Ganancias

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 may 2026, 23:47 UTC

Ganancias

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 may 2026, 23:46 UTC

Ganancias

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 may 2026, 23:46 UTC

Ganancias

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 may 2026, 23:28 UTC

Charlas de Mercado

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 may 2026, 23:00 UTC

Charlas de Mercado

Australia's One Nation Party Leads In The Polls -- Market Talk

14 may 2026, 22:46 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 may 2026, 22:46 UTC

Charlas de Mercado

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 may 2026, 22:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 may 2026, 22:35 UTC

Charlas de Mercado

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 may 2026, 22:11 UTC

Adquisiciones, fusiones, absorciones

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 may 2026, 22:06 UTC

Charlas de Mercado

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 may 2026, 22:04 UTC

Ganancias

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 may 2026, 22:04 UTC

Ganancias

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 may 2026, 22:04 UTC

Ganancias

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 may 2026, 22:00 UTC

Ganancias

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 may 2026, 21:55 UTC

Ganancias

Nu Holdings 1Q EPS 18c >NU

14 may 2026, 21:55 UTC

Ganancias

Nu Holdings 1Q Rev $4.97B >NU

Comparación entre iguales

Cambio de precio

Day One Biopharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

-3.62% descenso

Estimación a 12 Meses

Media 20.75 USD -3.62%

Máximo 21.5 USD

Mínimo 17 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Day One Biopharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Day One Biopharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

6.26 / 7.47Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Sentimiento

By Acuity

171 / 346 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.